Benefits
Studied for safety and tolerability in healthy adults
Three Phase I studies gave baicalein tablets to healthy adults at single doses up to 2800 mg and at 200 to 600 mg three times a day. Reported side effects were mild and cleared on their own, with no serious events and no signs of liver or kidney harm on blood tests. The two larger studies were run by a drug maker.
Absorption depends on gut bacteria converting it to baicalein
On its own, baicalin is barely taken up from the gut. Bacteria in the colon remove its sugar group to form baicalein, which the gut lining can absorb and then turns back into baicalin in the blood. This has been shown with human stool bacteria in a laboratory colon model and in animals, and explains why little intact baicalin reaches the bloodstream.
Inflammatory signaling in laboratory and animal studies
In cell and animal studies, baicalin and baicalein act on inflammatory signaling, including the NF-kB pathway and messengers such as IL-6 and TNF-alpha. These are laboratory and animal findings. No study on this page measured inflammation in a person taking baicalin, and in the healthy-adult trials a rise in the blood marker hs-CRP was recorded as a side effect in some people.
Antioxidant activity in laboratory studies
In test-tube assays the flavones neutralize reactive oxygen species and bind metal ions such as iron, which slows oxidative damage to fats. Whether this changes antioxidant status in a person taking baicalin has not been tested in any study cited here, so it remains a laboratory observation.
Metabolic measures in animal studies
Reviews of animal work report that baicalin and baicalein affect body weight, blood lipids, blood sugar and fat build-up in the liver in rodent models of overfeeding. None of this has been confirmed in a human trial, and these animal findings are not a basis for using baicalin for weight, blood sugar or liver conditions.
Mechanism of action
Converted to its aglycone before absorption
Baicalin carries a sugar (glucuronide) group that keeps it from crossing the gut wall. Colonic bacteria with beta-glucuronidase enzymes cut off that group to release baicalein, which is absorbed and then re-attached to a glucuronide in the gut and liver, so baicalin is the main form measured in the blood.
Inflammatory pathway signaling (laboratory)
In preclinical models the flavones dampen NF-kB-driven release of inflammatory messengers and inhibit lipoxygenase enzymes. This is offered as an explanation for the traditional use of skullcap root, not as evidence that baicalin lowers inflammation in people.
Free radical scavenging (laboratory)
In test-tube studies baicalein donates hydrogen atoms to unstable free radicals and binds metal ions, which can slow the chain reactions that damage cell membranes. These are laboratory measurements that have not been shown to produce antioxidant changes in people.
Clinical trials
Single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose Phase I study of oral baicalein tablets, funded by the tablet's maker (Li et al. 2021, Clin Transl Sci)
36 healthy Chinese adults given 200, 400 or 600 mg baicalein or placebo, once on days 1 and 10 and three times daily on days 4 to 9.
Baicalein was generally safe and well tolerated; all side effects were mild and resolved on their own, and the one moderate event, a fever, was judged unrelated to baicalein. Baicalein was absorbed quickly, with blood levels peaking within about 2 hours. The study measured safety and drug levels only, not any health outcome.
Single-center, randomized, double-blind, placebo-controlled single-dose Phase I study with a food-effect arm, funded by the tablet's maker (Dong et al. 2021, J Ethnopharmacol)
Healthy Chinese adults across three parts: 60 in a single-dose safety study (100 to 800 mg), 40 in a pharmacokinetic study (200 to 800 mg) and 10 in a 400 mg food-effect arm.
Among 80 adults evaluated for safety, side effects occurred in about 40 percent and were all mild; the most common were a rise in the blood marker hs-CRP and higher triglycerides. Blood exposure rose less than in proportion to the dose. The study assessed safety and drug levels, not whether baicalein helps any condition.
Phase I, randomized, double-blind single ascending dose study of baicalein chewable tablets measuring baicalein and its metabolite baicalin, with industry funding (Li et al. 2014, J Ethnopharmacol)
72 healthy adults given single oral doses of 100 to 2800 mg of baicalein.
Single doses up to 2800 mg were well tolerated; the eleven treatment-related side effects were all mild, with no serious events and no sign of liver or kidney toxicity on blood tests. Less than 1 percent of the dose left in urine and about 27 percent of baicalein was recovered unchanged in stool. Baicalein appeared in blood mostly as its metabolite baicalin.
Laboratory study using an artificial colon model seeded with gut bacteria from the stool of healthy volunteers (Seradj et al. 2024, Pharmazie)
No people were dosed; stool samples from healthy volunteers supplied the bacteria for an in vitro ascending-colon model.
Baicalin was converted to baicalein only when gut bacteria were present, and not without them, confirming that colonic bacterial enzymes (beta-glucuronidases) break down poorly absorbed baicalin to the absorbable aglycone baicalein. This is a laboratory model, not a test of any health effect.
Laboratory and animal pharmacokinetic study in conventional and germ-free rats (Akao et al. 2000, J Pharm Pharmacol)
Rats, including germ-free rats that lack gut bacteria; no human participants.
Oral baicalin barely entered the blood of germ-free rats but was absorbed normally in rats with gut bacteria, appearing in blood as baicalin after being broken down to baicalein in the gut and re-attached to a glucuronide in the body. An animal study that explains the absorption route; it does not show a health benefit.